Fig. 5.

TCRβ seqencing. (A) TCR fraction in PBMCs and in tumor at baseline (Pre-TX), after limb infusion (post-ILI) and after the fourth dose of Ipilimumab (Post-IPI). Note that there is not a difference in the starting T cells between patients that derived benefit (PFS at one year versus not). Although there was not an overall change in T cells in the periphery, there T cells in the tumors of patients with PFS at one year were somewhat increased, although the change was not significant. (B) Box-and-whisker plots of the clonality of the TCR fraction. The clonality did not change in the PBMC; however, there was a significant increase in clonality, or a less even distribution of T cell clones, in the tumor versus the PBMC (P = 0.015, by Wiloxon signed rank test), after combination treatment.